| Association between Bone Marrow Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer. |
|
Hee Yun Seol, Jeong Ha Mok, Seong Hoon Yoon, Ji Eun Kim, Ki Uk Kim, Hye Kyung Park, Seong Jang Kim, Yun Seong Kim, Min Ki Kim, Soon Kew Park |
1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. snkpark@pusan.ac.kr
2Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea. |
|
|
| Abstract |
BACKGROUND
(18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for the diagnosis and staging of non-small cell lung cancer (NSCLC). The aim of this study is to determine whether the bone marrow hypermetabolism seen on FDG-PET predicts a response to chemotherapy in patients with NSCLC. METHODS: We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of chemotherapy. RESULTS: Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively). CONCLUSION: The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients. |
| Key Words:
Non-small cell lung cancer, Bone marrow, (18)F-Fluorodeoxyglucose positron emission tomography, Chemotherapy |
|
PDF Links
Full text via DOI
Download Citation
